Pharmaceuticals News 31 October 2025

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

FDA Setback: Complete Response Letter Halts Lead Drug Ambitions Biohaven’s recent troubles center on VYGLXIA (troriluzole) – its lead drug candidate for spinocerebellar ataxia (SCA), a degenerative brain disorder that currently has no approved treatment reuters.com. On November 4, 2025,

5 November 2025

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Financial Health and Earnings Trends Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quarters investing.com, marking a sustained rebound after a difficult

5 November 2025

Company Analysis · Earnings Reports · Investment Strategies · NYSE:TEVA · Pharmaceuticals · Stock Market

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value reuters.com. The Danish pharmaceutical giant

5 November 2025

Business News · Healthcare Industry · NYSE:NVO · Pharmaceuticals · Stock Market · Weight Loss

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share

4 November 2025

Business News · Healthcare Industry · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Obesity Treatment · Pharmaceuticals

Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

4 November 2025

Artificial Intelligence · Business · Corporate Leadership · NYSE:PLTR · Pharmaceuticals · Technology News

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus

4 November 2025

Drug Development · Earnings Reports · Market Analysis · NYSE:PFE · Obesity Treatments · Pharmaceuticals

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) sharewise.com. In the past three years, the shares have

3 November 2025

Dividends · Investment Strategies · Market Outlook · NYSE:PFE · Pharmaceuticals · Stocks

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Performance: From Penny Stock to Momentum Rocket Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward

3 November 2025

Biotech · Company News · Investing · NASDAQ:RANI · Pharmaceuticals · Stock Market

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering

2 November 2025

Health Industry · Investing · Market News · NYSE:PFE · Pharmaceuticals · Stocks

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Market Snapshot (pre-market Nov 3) As of Oct. 31 close, Eli Lilly (NYSE:LLY) was around $862–864 (with after-hours ~864) stockanalysis.com marketbeat.com. That’s up ~9–10% from early October nasdaq.com. Trading volumes have been heavy, and LLY remains near its 52-week high

2 November 2025

Eli Lilly · Health Industry · NYSE:LLY · Pharmaceuticals · Pre-Market · Stock Forecast

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Stock Performance and Recent Movement Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai (up to $1.085B deal) and a simultaneous $60M financing sent

1 November 2025

Biotech · Health Innovation · NASDAQ:RANI · Obesity · Pharmaceuticals · Stock Analysis

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on record ts2.tech reportify.cn. This vastly outperforms both the S&P 500

31 October 2025

Financial Analysis · Healthcare Industry · Investment Strategies · NYSE:ABBV · Pharmaceuticals · Stock Market

Pharmaceuticals News 31 October 2025 - 5 November 2025